Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech ...
If you’ve been the victim of fraud, you’re likely already a lead on a ‘sucker list’ – and if you’re not careful, your ordeal may be about to get worse. Threat actors are using AI to supercharge ...
A high-efficiency SQL development workflow powered by Github Copilot — from natural language to optimized queries with automated validation and feedback loops.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results